Therapeutic developments in peroxisome biogenesis disorders

Bibliography

• VAN DEN BOSCH H, SCHUTGENS RB, WANDERS RJ,TAGER JM: Biochemistry of peroxisomes. Ann. Rev. Biochem. (1992) 61:157–197.
   PubMed Web of Science ®Google Scholar
• SUBRAMANI S: Components involved in peroxisome import, biogenesis, proliferation, turnover and movement. Physiol. Rev. (1998) 78:171–188.
   PubMed Web of Science ®Google Scholar
• ••A detailed description of peroxins.
   Google Scholar
• WANDERS R: Peroxisomal disorders: clinical,biochemical and molecular aspects. Neurochem. Res. (1999) 24:565–580.
   PubMed Web of Science ®Google Scholar
• GOULD SJ, RAYMOND GV, VALLE D: The peroxisome biogenesis disorders. In: The Metabolic and Molecular Bases of Inherited Disease. Scriver C, Beaudet A, Sly W, Valle D. (Eds.), McGraw-Hill, New York, USA (2000). (In Press).
   Google Scholar
• ••Excellent review of peroxisome biogenesis disorders andfunctions of peroxins.
   Google Scholar
• MOSER HW, MOSER AB: Peroxisomal disorders: overview. Ann. NY Acad. ScL (1996) 804:427–441.
   PubMed Web of Science ®Google Scholar
• MOSER AB, RASMUSSEN M, NAIDU S et al: Phenotype of patients with peroxisomal disorders subdivided into sixteen complementation groups. J Pediatr. (1995) 127:13–22.
   PubMed Web of Science ®Google Scholar
• SHIMOZAWA N, SUZUKI Y, ZHANG Z et al: Genetic basis of peroxisome-assembly mutants of humans, Chinese hamster ovary cells and yeast; identification of a new complementation group of peroxisome-biogeneis disorders apparently lacking peroxisomal-membrane ghosts. Am. J. Hum. Genet. (1998) 63:1898–1903.
   PubMed Web of Science ®Google Scholar
• BRUL S, WESTERVELD A, STRIJLAND A et al: Genetic heterogeneity in the cerebro-hepato-renal (Zellweger) syndrome and other inherited disorders with a generalized impairment of peroxisomal functions: A study using complementation analysis. J. an. Invest. (1988) 81:1710–1715.
   PubMed Web of Science ®Google Scholar
• ROSCHER AA, HOEFLER S, HOEFLER G et al.: Genetic and phenotypic heterogeneity in disorders of peroxisome biogenesis- A complementation study involving cell lines from 19 patients. Pediatr. Res. (1989) 25:67–72.
   Google Scholar
• POLL-THE BT, SKJELDAL OH, STOKKE O et al.: Phytanic acid alpha-oxidation and complementation analysis of classical Refsum and peroxisomal disorders. Hum. Genet. (1988) 81:175–181.
   Web of Science ®Google Scholar
• MCGUINNESS MC, MOSER AB, MOSER HW, WATKINS P: Peroxisomal disorders: Complementation analysis using beta-oxidation of very long chain fatty acids. Biochem. Biophys. Res. Commum. (1990) 1 72:364–369.
   Google Scholar
• SANTOS MJ, HOEFLER S, MOSER AB, MOSER HW, LAZAROW PB: Peroxisome assembly mutations in humans: structural heterogeneity in Zellweger syndrome. J. Cell Physiol. (1992) 151:103–112.
   PubMed Web of Science ®Google Scholar
• YAJIMA S, SUZUKI Y, SHIMOZAWA N et al.: Complemen-tation study of peroxisome-deficient disorders by immunofluorescence staining and characterization of fused cells. Hum. Genet. (1992) 88:491–499.
   PubMed Web of Science ®Google Scholar
• MOSER HW: Genotype-phenotype correlations in disorders of peroxisome biogenesis. Mol. Genet. Metab. (1999) 68:316–327.
   PubMed Web of Science ®Google Scholar
• ••A detailed description of genotype and PBD phenotypecorrelations.
   Google Scholar
• DODT G, BRAVERMAN N, VALLE D, GOULD SJ: From expressed sequence tags to peroxisome biogenesis disorder genes. Ann. NY Acad. Sci. (1996) 8 0 4:516–523.
   Google Scholar
• WILSON GN, HOLMES RG, CUSTER J et al: Zellwegersyndrome: diagnostic assays, syndrome delineation and potential therapy. Am. J Hum. Genet. (1986) 24:69–82.
   Web of Science ®Google Scholar
• SCHUTGENS RB, HEYMANS HS, WANDERS RJ, VAN DEN BOSCH H, TAGER JM: Peroxisomal disorders: a newly recognized group of genetic diseases. Eur. j Pediatr. (1986) 144:430–440.
   PubMed Web of Science ®Google Scholar
• KELLEY RI: The cerebrohepatorenal syndrome of Zellweger, morphologic and metabolic aspects. Am. J Med. Genet. (1983) 16:503–517.
   PubMed Web of Science ®Google Scholar
• GOVAERTS L, MONNENS L, TEGELAERS W, TRIJBELS F,VAN RAAY-SELTEN A: Cerebro-hepatorenal syndrome of Zellweger: Clinical symptoms and relevant labora-tory findings in 16 patients. Eur. j Pediatr. (1982) 139:125–128.
   PubMedGoogle Scholar
• LAZAROW PB: Peroxisome structure, function andbiogenesis - human patients and yeast mutants show strikingly similar defects in peroxisome biogenesis. J. Neuropath. Exp. Neurol. (1995) 54:720–725.
   PubMed Web of Science ®Google Scholar
• TORVIK A, TORP S, KASE BE, EK J, SKJEDAL O, STOKKE O:Infantile Refsum's disease: A generalized peroxisomal disorder. Case report with post-mortem examination. Neurol Sci. (1988) 85:39–53.
   Google Scholar
• BRAVERMAN N, STEEL G, OBIE C et al: Human PEX7encodes the peroxisomal PTS2 receptor and is respon-sible for rhizomelic chondrodysplasia punctata. Nature Genet. (1997) 15:369–376.
   PubMed Web of Science ®Google Scholar
• LAZAROW PB, MOSER HW: Disorders of peroxisomebiogenesis. In: The Metabolic and Molecular Bases of Inherited Disease. Scriver CR Beaudet A, Sly WS, Valle D (Eds.), McGraw-Hill, New York, USA (1995):2287–2324.
   Google Scholar
• PORTSTEFFEN H, BEYER A, BECKER E etal: Human PEX1is mutated in complementation group 1 of the peroxi-some biogenesis disorders. Nature Genet. (1997) 17:449–452.
   PubMed Web of Science ®Google Scholar
• REUBER BE, GERMAIN-LEE E, COLLINS CS et al.:Mutations in PEX1 are the most common cause of peroxisome biogenesis disorders. Nature Genet. (1997) 17:445–448.
   PubMed Web of Science ®Google Scholar
• CHANG CC, GOULD SJ: Phenotype-genotype relation-ships in complementation group 3 of the peroxisome-biogenesis disorders. Am. J Hum. Genet. (1998) 63:1294–1306.
   PubMed Web of Science ®Google Scholar
• YAHRAUS T, BRAVERMAN N, DODT G et al.: The peroxi-some biogenesis disorder group 4 gene, PXAAA1, encodes a cytoplasmic ATPase required for stability of the PTS1 receptor. EMBO J (1996) 15:2914–2923.
   PubMed Web of Science ®Google Scholar
• WARREN DS, MORRELL JC, MOSER HW, VALLE D, GOULDSJ: Identification of PEX10, the gene defective in complementation group 7 of the peroxisome-biogenesis disorders. Am. J. Hum. Genet. (1998) 63:347–359.
   PubMed Web of Science ®Google Scholar
• WEI H-W, KEMP S, MCGUINNESS MC, MOSER AB, SMITH KD: Pharmacologic induction of peroxisomes in peroxisome biogenesis disorders. Ann. Neurol (2000) 47:286–296.
   PubMed Web of Science ®Google Scholar
• ••A description of the correlation between peroxisomenumber and PBD phenotype and the effect of 4-phenylbutyrate on PBD fibroblasts.
   Google Scholar
• CHANG C, SOUTH S, WARREN D et al.: Metabolic control of peroxisome abundance./ Cd/Sci. (1999) 112:105–120.
   Google Scholar
• •A description of the correlation between peroxisome number and PBD phenotype.
   Google Scholar
• VOSS A, REINHART M, SANKARAPPA S, SPRECHER H: The metabolism of 7, 10, 13, 16, 19-docosapentaenoic acid to 4, 7, 10, 13,16,19,-docosahexaenoic acid in rat liver is independent of a 4-desaturase. J. Biol. Chem. (1991) 266:19995–20000.
   PubMed Web of Science ®Google Scholar
• MARTINEZ M: Docosahexaenoic acid therapy in DHA-deficient patients with disorders of peroxisomal biogenesis. Lipids (1996) 31:S145–152.
   PubMed Web of Science ®Google Scholar
• MARTINEZ M, VAZQUEZ E: MRI evidence that docosa-hexanoic acid ethyl ester improves myelination in generalized peroxisomal disorders. Neurology (1998) 51:26–32.
   PubMed Web of Science ®Google Scholar
• MOSER AB, JONES DS, RAYMOND GV, MOSER HW: Plasma and red blood cell fatty acids in peroxisomal disorders. Neurochem. Res. (1999) 24:187–197.
   PubMed Web of Science ®Google Scholar
• JANSSEN A, BAES M, GRESSENS GP, MANNAERTS P, DECLERCQ P, VAN VELDHOVEN PP: Docosahexaenoic acid is not a major pathogenic factor in peroxisome-deficient mice. Lab. Invest. (2000) 80:31–35.
   PubMed Web of Science ®Google Scholar
• BLOMSTRAND R: Digestion, absorption and metabo-lism of chimyl alcohol fed as free alcohol or alkoxydi-glyceride. Proc. Soc. Exp. Biol. Med. (1959) 102:662–665.
   PubMedGoogle Scholar
• HOLMES RD, WILSON GN, HAJRA A: Oral ether lipid therapy in patients with peroxisomal disorders. J. Inherit. Metab. Dis. (1987) 10 (Suppl.) :239–241.
   Google Scholar
• GREENBERG CR, HAJRA AK, MOSER AB: Triple therapy of a patient with a generalized peroxisomal disorder. Am. J. Hum. Genet. (1987) 41 (Suppl.):A64.
   Google Scholar
• SETCHELL KDR, BRAGETTI P, ZIMMER-NECHEMIAS L et al.: Oral bile acid treatment and the patient with Zellweger syndrome. Hepatology (1992) 15:198–207.
   PubMed Web of Science ®Google Scholar
• MOSER HW, BOREL J, ODONE A et al.: A new dietary therapy for adrenoleukodystrophy: biochemical and preliminary clinical results in 36 patients. Ann. Neurol. (1987) 21:240–249.
   PubMed Web of Science ®Google Scholar
• CHRISTENSEN E, GRONN M, HAGVE TA, KASE BF, CHRISTOPHERSEN BO: Adrenoleukodystrophy. The chain shortening of erucic acid (22:1(n-9)) and adrenic acid (22:4(n-6)) is deficient in neonatal adrenoleukodystrophy and normal in X-linked adr en oleukodistrophy skin fibroblasts. Biochim. Biophys. Acta (1989) 1002:79–83.
   Google Scholar
• BARTH PG, MARTINEZ M, APKARIAN P, HAVERKORT EB, WANDERS RJA, SCHUTGENS RBH: Disorders of peroxi-some biogenesis: classification and treatment. In: Functions and biogenesis of peroxisomes in relation to human disease. Schutgens RBH, Wanders RJA (Eds.), Elsevier Scientific Publishers, Amsterdam, The Netherlands (1994):210–226.
   Google Scholar
• ••A description of therapeutic attempts to modify diet in PBDpatients.
   Google Scholar
• REDDY JK, CHU R: Peroxisome proliferator-induced pleiotropic responses: pursuit of a phenomenon. Ann. NY Acad. Sci. (1996) 804:176–201.
   PubMed Web of Science ®Google Scholar
• BJORKHEM I, BLOMSTRAND S, GLAUMANN H, STRANDVIK B: Unsuccessful attempts to induce peroxi-somes in two cases of Zellweger disease by treatment with clofibrate. Pediatr. Res. (1985)19:590–593.
   PubMed Web of Science ®Google Scholar
• LAZAROW P, BLACK V, SHIO H et al.: Zellweger syndrome: Biochemical and morphological studies on two patients treated with clofibrate. Pediatr. Res. (1985) 19:1356–1364.
   PubMed Web of Science ®Google Scholar
• KEMP S, WEI HM, LU JF et al.: Gene redundancy and pharmacological gene therapy: implications for X-linked adrenoleukodystrophy. Nature Med. (1998) 4:1261–1268.
   PubMed Web of Science ®Google Scholar
• ••A description of the effect of 4-phenylbutyrate in X-ALD.
   Google Scholar
• CARSTEA ED, MURRAY GJ, O'NEILL RR: Molecular andfunctional characterization of the murine glucocere-broside gene. Biochem. Biophys. Res. Commun. (1992) 184:1477–1483.
   PubMedGoogle Scholar
• DENG G, LIU G, HU L, GUM JR, KIM YS: Transcriptionalregulation of the human placental-like alkaline phosphatase gene and mechanisms involved in its induction by sodium butyrate. Cancer Res. (1992) 52:3378–3383.
   PubMed Web of Science ®Google Scholar
• FERGEAU CJ, HELGASON CD, BLEACKLEY RC: Two cytotoxic cell proteinase genes are differentially sensitive to sodium butyrate. Nucleic Acids Res. (1992) 20:3113–3119.
   PubMed Web of Science ®Google Scholar
• LIU L, HUDGINS WR, MILLER AC, CHEN LC, SAMID D: Transcriptional upregulation of TGF-alpha by phenylacetate and phenylbutyrate is associated with differentiation of human melanoma cells. Cytokine (1995) 7:449–456.
   PubMed Web of Science ®Google Scholar
• MAESTRI NE, BRUSILOW SW, CLISSOLD DB, BASSETT SS: Long-term treatment of girls with ornitine transcarba-mylase deficiency. N Engl. J. Med. (1996) 335:855–859.
   PubMed Web of Science ®Google Scholar